[go: up one dir, main page]

PE20040988A1 - Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) - Google Patents

Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)

Info

Publication number
PE20040988A1
PE20040988A1 PE2003000940A PE2003000940A PE20040988A1 PE 20040988 A1 PE20040988 A1 PE 20040988A1 PE 2003000940 A PE2003000940 A PE 2003000940A PE 2003000940 A PE2003000940 A PE 2003000940A PE 20040988 A1 PE20040988 A1 PE 20040988A1
Authority
PE
Peru
Prior art keywords
tgf
inhibitors
growth factor
transforming growth
pyrazole compounds
Prior art date
Application number
PE2003000940A
Other languages
English (en)
Inventor
Michael John Munchhof
Laura Cook Blumberg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040988A1 publication Critical patent/PE20040988A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA Ia, DONDE R1 ES ANILLO SATURADO, INSATURADO O AROMATICO C3-C20, MONO- O BICICLICO, ENTRE OTROS; R3 ES H, HALO, HALOALQUILO C1-C6, ENTRE OTROS; R4 ES H, HALO, HALOALQUILO C1-C6, ENTRE OTROS; S ES 1-5. R6 ES FENILO, HETEROARILO C5-C10, HETEROCICLO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS:4-[3-(6-METILPIRIDIL-2-IL)-1H-PIRAZOL-4-IL-QUINOLINA, 2-(4-BENZO[1,3]DIOXOL-5-IL-1H-PIRAZOL-3-IL)-6-METILPIRIDINA Y 4-(3-PIRIDIN-2-IL-1H-PIRAZOL-4-IL)QUINOLINA; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMADOR (TGF) Y SON UTILES EN LA PREVENCION O TRATAMIENTO DE PATOLOGIAS RELACIONADAS CON TGF TALES COMO CANCER Y ENFERMEDADES FIBROTICAS
PE2003000940A 2002-09-18 2003-09-15 Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) PE20040988A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41214602P 2002-09-18 2002-09-18
US48454303P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
PE20040988A1 true PE20040988A1 (es) 2004-12-25

Family

ID=32033585

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000940A PE20040988A1 (es) 2002-09-18 2003-09-15 Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)

Country Status (27)

Country Link
US (4) US6958354B2 (es)
EP (2) EP1542684B1 (es)
JP (1) JP4519657B2 (es)
KR (1) KR20050044807A (es)
CN (1) CN1681501A (es)
AP (1) AP2005003263A0 (es)
AR (1) AR041272A1 (es)
AT (1) ATE450258T1 (es)
AU (1) AU2003259475A1 (es)
BR (1) BR0314302A (es)
CA (1) CA2496295C (es)
CO (1) CO5550456A2 (es)
DE (1) DE60330362D1 (es)
EA (1) EA200500377A1 (es)
EC (1) ECSP055679A (es)
ES (1) ES2335099T3 (es)
HR (1) HRP20050247A2 (es)
IS (1) IS7698A (es)
MA (1) MA27440A1 (es)
MX (1) MXPA05002376A (es)
NO (1) NO20050838L (es)
OA (1) OA12929A (es)
PA (1) PA8583201A1 (es)
PE (1) PE20040988A1 (es)
PL (1) PL375979A1 (es)
UY (1) UY27985A1 (es)
WO (1) WO2004026306A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314302A (pt) * 2002-09-18 2005-07-05 Pfizer Producs Inc Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
KR20050057392A (ko) * 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
EP1786803A1 (en) * 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
WO2006028029A1 (ja) * 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
AU2005295734A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
ZA200804496B (en) * 2005-12-16 2009-09-30 Alcon Inc Control of intraocular pressure using ALK5 modulation agents
AP2527A (en) 2006-10-31 2012-12-06 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptorantagonists
EA201000113A1 (ru) * 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
EP3089971B1 (en) 2014-01-01 2020-07-29 Medivation Technologies LLC Compounds and methods of use
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
ES2787449T3 (es) * 2016-06-13 2020-10-16 Genfleet Therapeutics Shanghai Inc Compuesto de alfa y beta-amida insaturada derivado de benzotriazol usado como inhibidor de TGF-betaRI
JP2019531753A (ja) * 2016-10-26 2019-11-07 アイカーン スクール オブ メディシン アット マウント サイナイ 膵β細胞における細胞増殖を増加させるための方法、治療方法、及び組成物
MX2019004822A (es) * 2016-11-14 2019-09-11 Jiangsu Hengrui Medicine Co Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
CN111936490A (zh) 2017-11-20 2020-11-13 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
CA3085498C (en) * 2017-12-13 2023-04-18 Genfleet Therapeutics (Shanghai) Inc. Crystal form and salt form of tgf-.beta.ri inhibitor and preparation method therefor
US11788064B2 (en) 2018-01-05 2023-10-17 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
EP3768267B1 (en) 2018-03-20 2025-05-14 Icahn School of Medicine at Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
WO2020003219A1 (en) * 2018-06-29 2020-01-02 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives as insecticides and fungicides
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
MA54448A (fr) 2018-12-11 2021-10-20 Theravance Biopharma R&D Ip Llc Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
CN110467601B (zh) * 2019-08-29 2021-07-02 杭州市西溪医院 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用
CA3160307A1 (en) 2019-11-22 2021-05-27 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
AR120578A1 (es) 2019-11-28 2022-02-23 Origo Biopharma S L DERIVADOS DE BENCILAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 (TGFbRI) / ALK5

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4925857A (en) * 1989-03-22 1990-05-15 Sterling Drug Inc. Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU755498B2 (en) 1997-05-22 2002-12-12 G.D. Searle & Co. 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
AU4798000A (en) 1999-04-09 2000-11-14 Smithkline Beecham Corporation Triarylimidazoles
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
WO2002040468A1 (en) 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE291020T1 (de) * 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
JP2004526727A (ja) 2001-03-09 2004-09-02 ファイザー・プロダクツ・インク ベンゾイミダゾール抗炎症化合物
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
TW200417547A (en) 2002-07-31 2004-09-16 Smithkline Beecham Corp Compounds
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
BR0314302A (pt) * 2002-09-18 2005-07-05 Pfizer Producs Inc Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
AU2003263431A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
JP2006502236A (ja) 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体
KR20050057392A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

Also Published As

Publication number Publication date
PA8583201A1 (es) 2004-04-23
JP4519657B2 (ja) 2010-08-04
KR20050044807A (ko) 2005-05-12
CA2496295C (en) 2010-11-23
EP1542684A2 (en) 2005-06-22
EP2165708A3 (en) 2010-07-28
OA12929A (en) 2006-10-13
CO5550456A2 (es) 2005-08-31
BR0314302A (pt) 2005-07-05
ATE450258T1 (de) 2009-12-15
DE60330362D1 (de) 2010-01-14
CA2496295A1 (en) 2004-04-01
US20060025451A1 (en) 2006-02-02
UY27985A1 (es) 2004-04-30
MXPA05002376A (es) 2005-05-23
IS7698A (is) 2005-02-17
ES2335099T3 (es) 2010-03-22
WO2004026306A2 (en) 2004-04-01
PL375979A1 (en) 2005-12-12
US6958354B2 (en) 2005-10-25
US20040116474A1 (en) 2004-06-17
JP2006507353A (ja) 2006-03-02
AR041272A1 (es) 2005-05-11
US20100056571A1 (en) 2010-03-04
WO2004026306A3 (en) 2004-07-01
US7151110B2 (en) 2006-12-19
ECSP055679A (es) 2005-05-30
EA200500377A1 (ru) 2005-08-25
HRP20050247A2 (en) 2005-10-31
CN1681501A (zh) 2005-10-12
NO20050838L (no) 2005-05-18
MA27440A1 (fr) 2005-07-01
US20070117850A1 (en) 2007-05-24
EP2165708A2 (en) 2010-03-24
EP1542684B1 (en) 2009-12-02
AP2005003263A0 (en) 2005-03-31
AU2003259475A1 (en) 2004-04-08
US7638537B2 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
PE20040988A1 (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
JO2282B1 (en) Oxazole derivatives
IL149150A0 (en) 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
MY135841A (en) Novel benzodioxoles
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
NO20062130L (no) 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft
PE20090837A1 (es) Nuevos compuestos quimicos
NZ525700A (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
TW200732339A (en) Nitrogen-containing bicyclic heteroaryl compounds and methods of use
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
PE20071080A1 (es) Compuestos de pirimidinona biciclicos como inhibidores de la integrasa de hiv
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
SG146658A1 (en) Haloalkyl containing compounds as cysteine protease inhibitors
PE20050076A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
ATE365730T1 (de) Neuartige verbindungen
RU2383533C2 (ru) Алкилированные производные пиридина в качестве ингибиторов 11-бета при диабете
HRP20050803B1 (hr) Novitetna kristalna modifikacija anhidrata boskalida
PE20030037A1 (es) Derivados de cianoantranilamida como inhibidores de la tirosina cinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal